Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy
Abstract The two main objectives of this analysis were to (i) characterize the relationship between immunoglobulin (Ig) exposure and chronic inflammatory demyelinating polyneuropathy (CIDP) disease severity using data from 171 patients with CIDP who received either subcutaneous Ig (IgPro20; Hizentra...
Saved in:
Main Authors: | Michael A. Tortorici, Theresa Yuraszeck, David Cornblath, Vera Bril, Hans‐Peter Hartung, Gen Sobue, Richard A. Lewis, Ingemar S. J. Merkies, John‐Philip Lawo, Michaela Praus, Billie L. Durn, Orell Mielke, Xuewen Ma, Petra Jauslin, Marc Pfister, Ivo N. vanSchaik, the PATH study group |
---|---|
Format: | article |
Language: | EN |
Published: |
Wiley
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/864b1de80a0d49abab9c2cf35b4c5ae2 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The characteristics of chronic inflammatory demyelinating polyneuropathy in patients with and without diabetes--an observational study.
by: Samantha K Dunnigan, et al.
Published: (2014) -
Evolving Immunologic Perspectives in Chronic Inflammatory Demyelinating Polyneuropathy
by: Rajabally YA, et al.
Published: (2020) -
Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins
by: Mohamed Mahdi-Rogers, et al.
Published: (2010) -
Metaheuristics for pharmacometrics
by: Seongho Kim, et al.
Published: (2021) -
Corneal inflammatory cell infiltration predicts disease activity in chronic inflammatory demyelinating polyneuropathy
by: Jeremias Motte, et al.
Published: (2021)